Tru-1 GLP-1
Genetic Test
GLP-1 Response Stratification for Precision Obesity Programs
Tru-1 analyzes genetic variants associated with GLP-1 medication response variability, helping clinicians and patients understand individual factors that may influence weight-loss effectiveness, gastrointestinal tolerability, appetite regulation, metabolic processing, and long-term adherence — before committing to a treatment pathway.
What It May Help Inform
- GLP-1 response variability and expected benefit range
- GI tolerability considerations
- Appetite regulation pathway insights
- Metabolic processing tendencies
- Persistence and adherence risk factors
- Pathway decision support (GLP-1, surgical, hybrid)
Response Profiles
Favorable GLP-1 Profile
Genetic factors associated with stronger expected response and tolerability.
Moderate Response Profile
Mixed signals — may benefit from additional clinical context before committing to a pathway.
Reduced Expected Benefit / Higher Support Profile
Factors that may warrant exploring alternative pathways or additional support strategies.
TRU-1 is designed to support provider decision-making, patient expectation-setting, and pathway selection — not to determine treatment. Genetic associations are informational and are not deterministic predictions. TRU-1 does not diagnose disease, select a medication or dose, or guarantee weight loss results.
Ready to bring TRU-1 to your practice?
Request partner information, pilot details, and clinic pricing. A CoGenetix team member will follow up within 1–2 business days.